GSK PLC Sponsored ADR (NYSE:GSK) Receives $53.00 Consensus PT from Analysts

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have earned a consensus recommendation of “Hold” from the ten brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $53.00.

Several research firms recently commented on GSK. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of GSK in a report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of GSK in a report on Thursday, July 30th. Wall Street Zen lowered GSK from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Jefferies Financial Group raised shares of GSK to a “strong-buy” rating in a research note on Friday, July 17th. Finally, Citigroup assumed coverage on shares of GSK in a report on Friday, July 24th. They set a “neutral” rating for the company.

GSK Stock Performance

NYSE GSK opened at $53.08 on Thursday. The firm has a market capitalization of $107.36 billion, a P/E ratio of 16.60, a PEG ratio of 3.04 and a beta of 0.36. The stock has a 50-day simple moving average of $51.80 and a two-hundred day simple moving average of $53.55. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. GSK has a fifty-two week low of $37.67 and a fifty-two week high of $61.69.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be given a dividend of $0.4515 per share. This is a boost from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 annualized dividend and a yield of 3.4%. The ex-dividend date is Friday, August 14th. GSK’s dividend payout ratio (DPR) is 55.94%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GSK. IHT Wealth Management LLC raised its position in shares of GSK by 1.3% in the fourth quarter. IHT Wealth Management LLC now owns 15,010 shares of the pharmaceutical company’s stock worth $736,000 after acquiring an additional 188 shares during the period. Bogart Wealth LLC grew its position in shares of GSK by 15.3% during the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock valued at $83,000 after acquiring an additional 200 shares during the period. Coston McIsaac & Partners grew its position in shares of GSK by 17.3% during the 4th quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock valued at $68,000 after acquiring an additional 206 shares during the period. First Horizon Corp increased its stake in shares of GSK by 78.7% in the 4th quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 236 shares in the last quarter. Finally, NBT Bank N A NY increased its stake in shares of GSK by 1.9% in the 1st quarter. NBT Bank N A NY now owns 16,568 shares of the pharmaceutical company’s stock valued at $914,000 after purchasing an additional 315 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.